Search results
Results from the WOW.Com Content Network
Generally, drugs outlined within the ATC code A10 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Anti-diabetic drugs .
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
Drug Main indication Trade name ... Drugs with sales above $5 billion in 2015 included: [3] [4] Rank Drug ... 3.86%: Novo Nordisk: Diabetes mellitus type 1 and 2: Oct ...
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup A10 is part of the anatomical group A Alimentary tract and ...
One of the most common drugs used in T2D, metformin is the drug of choice to help patients lower their blood sugar levels. Metformin is an example of a class of medicine called biguanides. [34] The medication works by reducing the new creation of glucose from the liver and by reducing absorption of sugar from food. [34]
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.
A large study of more than 2 million people evaluated GLP-1 agonists' benefits and risks. The study showed that GLP-1 agonists reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses, and several respiratory conditions. [5]